• Alene, K. A. et al. (2018) ‘Mental health disorders, social stressors, and health-related quality of life in patients with multidrug-resistant tuberculosis: A systematic review and meta-analysis’, Journal of Infection. Elsevier. doi: 10.1016/j.jinf.2018.07.007. [PubMed: 30036607] [CrossRef]

  • Alipanah, N. et al. (2018) Adherence interventions and outcomes of tuberculosis treatment: A systematic review and meta-analysis of trials and observational studies, PLOS Medicine. doi: 10.1371/journal.pmed.1002595. [PMC free article: PMC6029765] [PubMed: 29969463] [CrossRef]

  • Alonso-Coello, P. et al. (2016) ‘GRADE Evidence to Decision (EtD) frameworks: a systematic and transparent approach to making well informed healthcare choices. 1: Introduction’, BMJ. BMJ Publishing Group Ltd, 353. doi: 10.1136/bmj.i2016. [PubMed: 27353417] [CrossRef]

  • Anthenelli, R. M. et al. (2016) ‘Neuropsychiatric safety and efficacy of varenicline, bupropion, and nicotine patch in smokers with and without psychiatric disorders (EAGLES): a double-blind, randomised, placebo-controlled clinical trial’, The Lancet. Elsevier, 387(10037), pp. 2507–2520. doi: 10.1016/S0140-6736(16)30272-0. [PubMed: 27116918] [CrossRef]

  • Barnes, T. R. E. et al. (2007) ‘A UK audit of screening for the metabolic side effects of antipsychotics in community patients.’, Schizophrenia bulletin. Oxford University Press, 33(6), pp. 1397–403. doi: 10.1093/schbul/sbm038. [PMC free article: PMC2779874] [PubMed: 17483101] [CrossRef]

  • Bauer-Staeb, C. et al. (2017) ‘Prevalence and risk factors for HIV, hepatitis B, and hepatitis C in people with severe mental illness: a total population study of Sweden’, The Lancet Psychiatry. Elsevier, 4(9), pp. 685–693. doi: 10.1016/S2215-0366(17)30253-5. [PMC free article: PMC5573766] [PubMed: 28687481] [CrossRef]

  • Camilloni, L. et al. (2013) ‘Methods to increase participation in organised screening programs: a systematic review’, BMC Public Health, 13(1), p. 464. doi: 10.1186/1471-2458-13-464. [PMC free article: PMC3686655] [PubMed: 23663511] [CrossRef]

  • Capasso, R. M. et al. (2008) ‘Mortality in schizophrenia and schizoaffective disorder: An Olmsted County, Minnesota cohort: 1950–2005’, Schizophrenia Research. Elsevier, 98(1–3), pp. 287–294. doi: 10.1016/J.SCHRES.2007.10.005. [PubMed: 18031996] [CrossRef]

  • Centers for Disease Control and Prevention (2015) ‘Best Practices User Guide: Health Equity in Tobacco Prevention and Control’, pp. 1–52. Available at: https://www​.cdc.gov/tobacco​/stateandcommunity​/best-practices-health-equity/pdfs/.

  • Chou, R.-H. et al. (2017) ‘Antipsychotic treatment is associated with risk of atrial fibrillation: A nationwide nested case-control study.’, International journal of cardiology. Elsevier, 227, pp. 134–140. doi: 10.1016/j.ijcard.2016.11.185. [PubMed: 27855291] [CrossRef]

  • Correll, C. U. et al. (2015) ‘Effects of antipsychotics, antidepressants and mood stabilizers on risk for physical diseases in people with schizophrenia, depression and bipolar disorder’, World Psychiatry, 14, pp. 119–136. doi: 10.1002/wps.20204. [PMC free article: PMC4471960] [PubMed: 26043321] [CrossRef]

  • Correll, C. U. et al. (2017) ‘Prevalence, incidence and mortality from cardiovascular disease in patients with pooled and specific severe mental illness: a large‐scale meta‐analysis of 3,211,768 patients and 113,383,368 controls’, World Psychiatry, 16, pp. 163–180. [PMC free article: PMC5428179] [PubMed: 28498599]

  • Dennis, B. B. et al. (2015) ‘Opioid substitution and antagonist therapy trials exclude the common addiction patient: a systematic review and analysis of eligibility criteria’, Trials. London. doi: 10.1186/s13063-015-0942-4. [PMC free article: PMC4618532] [PubMed: 26489415] [CrossRef]

  • Dickerson, F. B. et al. (2006) ‘Obesity among individuals with serious mental illness’, Acta Psychiatrica Scandinavica, 113(4), pp. 306–313. doi: 10.1111/j.1600-0447.2005.00637.x. [PubMed: 16638075] [CrossRef]

  • Dipasquale, S. et al. (2013) ‘The dietary pattern of patients with schizophrenia: A systematic review’, Journal of Psychiatric Research. Pergamon, 47(2), pp. 197–207. doi: 10.1016/J.JPSYCHIRES.2012.10.005. [PubMed: 23153955] [CrossRef]

  • Druss, B. G. et al. (2000) ‘Mental Disorders and Use of Cardiovascular Procedures After Myocardial Infarction’, JAMA. American Medical Association, 283(4), p. 506. doi: 10.1001/jama.283.4.506. [PubMed: 10659877] [CrossRef]

  • Fekadu, A. et al. (2015) ‘Excess mortality in severe mental illness: 10-Year population-based cohort study rural Ethiopia’, British Journal of Psychiatry, 206(4), pp. 289–296. doi: 10.1192/bjp.bp.114.149112. [PubMed: 25657358] [CrossRef]

  • Di Florio, A., Craddock, N. and van den Bree, M. (2014) ‘Alcohol misuse in bipolar disorder. A systematic review and meta-analysis of comorbidity rates’, European Psychiatry. Elsevier, 29(3), pp. 117–124. doi: 10.1016/j.eurpsy.2013.07.004. [PubMed: 24075633] [CrossRef]

  • Gates, P. J. et al. (2016) ‘Psychosocial interventions for cannabis use disorder’, The Cochrane database of systematic reviews, p. CD005336. doi: 10.1002/14651858.CD005336.pub4. [PMC free article: PMC4914383] [PubMed: 27149547] [CrossRef]

  • Gierisch, J. M. et al. (2013) Interventions To Improve Cardiovascular Risk Factors in People With Serious Mental Illness, AHRQ Comparative Effectiveness Reviews. Available at: http://www​.epistemonikos​.org/documents/2a89f84579c968376a0ebb29ce11b78b2943d82f [PubMed: 23700634]

  • Gurpegui, M. et al. (2012) ‘Overweight and obesity in patients with bipolar disorder or schizophrenia compared with a non-psychiatric sample’, Progress in Neuro-Psychopharmacology and Biological Psychiatry. Elsevier, 37(1), pp. 169–175. doi: 10.1016/J.PNPBP.2012.01.014. [PubMed: 22326681] [CrossRef]

  • Guyatt, G. et al. (2011) ‘GRADE guidelines: 1. Introduction—GRADE evidence profiles and summary of findings tables’, Journal of Clinical Epidemiology. Pergamon, 64(4), pp. 383–394. doi: 10.1016/J.JCLINEPI.2010.04.026. [PubMed: 21195583] [CrossRef]

  • Henderson, D. C. et al. (2005) ‘Clozapine, diabetes mellitus, hyperlipidemia, and cardiovascular risks and mortality: results of a 10-year naturalistic study.’, The Journal of clinical psychiatry, 66(9), pp. 1116–21. [PubMed: 16187768]

  • De Hert, M. et al. (2011) ‘Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care’, World Psychiatry, 10(1), pp. 52–77. [PMC free article: PMC3048500] [PubMed: 21379357]

  • Hjorthøj, C. et al. (2015) ‘Association between alcohol and substance use disorders and all-cause and cause-specific mortality in schizophrenia, bipolar disorder, and unipolar depression: a nationwide, prospective, register-based study’, The Lancet Psychiatry, 2(9), pp. 801–808. doi: 10.1016/S2215-0366(15)00207-2. [PubMed: 26277044] [CrossRef]

  • Hughes, E. et al. (2016) ‘Prevalence of HIV, hepatitis B, and hepatitis C in people with severe mental illness: a systematic review and meta-analysis’, The Lancet Psychiatry. Elsevier, 3(1), pp. 40–48. doi: 10.1016/S2215-0366(15)00357-0. [PMC free article: PMC4703902] [PubMed: 26620388] [CrossRef]

  • Hunt, G. E. et al. (2014) ‘Psychosocial interventions for people with both severe mental illness and substance misuse’, Schizophr Bull. 2013/11/02 [PMC free article: PMC3885307] [PubMed: 24179148]

  • Jackson, J. G. et al. (2015) ‘A combined analysis of worldwide studies demonstrates an association between bipolar disorder and tobacco smoking behaviors in adults’, Bipolar Disorders, 17(6), pp. 575–597. doi: 10.1111/bdi.12319. [PubMed: 26238269] [CrossRef]

  • Jakobsen, A. S. et al. (2018) ‘Dietary patterns and physical activity in people with schizophrenia and increased waist circumference’, Schizophrenia Research. Elsevier. doi: 10.1016/J.SCHRES.2018.03.016. [PubMed: 29555213] [CrossRef]

  • Janney, C. A. (2013) ‘Sedentary behavior and psychiatric symptoms in overweight and obese adults with schizophrenia and schizoaffective disorders (WAIST Study)’. doi: 10.1016/j.schres.2013.01.010. [PMC free article: PMC3836608] [PubMed: 23410710] [CrossRef]

  • Janssen, E. M. et al. (2015) ‘Review of the Evidence: Prevalence of Medical Conditions in the United States Population with Serious Mental Illness’, General hospital psychiatry, pp. 199–222. doi: 10.1016/j.genhosppsych.2015.03.004. [PMC free article: PMC4663043] [PubMed: 25881768] [CrossRef]

  • Jørgensen, K. B., Nordentoft, M. and Hjorthøj, C. (2018) ‘Association between alcohol and substance use disorders and psychiatric service use in patients with severe mental illness: a nationwide Danish register-based cohort study’, Psychological Medicine. Cambridge University Press, pp. 1–9. doi: 10.1017/S0033291718000223. [PubMed: 29429425] [CrossRef]

  • Kakuma, R. et al. (2011) ‘Human resources for mental health care: current situation and strategies for action’, The Lancet. Elsevier, 378(9803), pp. 1654–1663. doi: 10.1016/S0140-6736(11)61093-3. [PubMed: 22008420] [CrossRef]

  • Kapczinski, F. et al. (2008) ‘Allostatic load in bipolar disorder: Implications for pathophysiology and treatment’, Neuroscience & Biobehavioral Reviews. Pergamon, 32(4), pp. 675–692. doi: 10.1016/J.NEUBIOREV.2007.10.005. [PubMed: 18199480] [CrossRef]

  • Kreyenbuhl, J. et al. (2010) ‘The Schizophrenia Patient Outcomes Research Team (PORT): Updated Treatment Recommendations 2009’, Schizophrenia Bulletin. Oxford University Press, 36(1), pp. 94–103. doi: 10.1093/schbul/sbp130. [PMC free article: PMC2800150] [PubMed: 19955388] [CrossRef]

  • Krupchanka, D. et al. (2018) ‘Mortality in people with mental disorders in the Czech Republic: a nationwide, register-based cohort study’, The Lancet Public Health, 3(6), pp. e289–e295. doi: 10.1016/S2468-2667(18)30077-X. [PubMed: 29884434] [CrossRef]

  • Kuo, S.-C. et al. (2013) ‘Incidence and outcome of newly-diagnosed tuberculosis in schizophrenics: a 12-year, nationwide, retrospective longitudinal study’, BMC Infectious Diseases. BioMed Central, 13(1), p. 351. doi: 10.1186/1471-2334-13-351. [PMC free article: PMC3729604] [PubMed: 23895638] [CrossRef]

  • Lamontagne-Godwin, F. et al. (2018) ‘Interventions to increase access to or uptake of physical health screening in people with severe mental illness: a realist review’, BMJ Open. British Medical Journal Publishing Group, 8(2). doi: 10.1136/bmjopen-2017-019412. [PMC free article: PMC5829934] [PubMed: 29440160] [CrossRef]

  • Lasser, K. et al. (2000) ‘Smoking and Mental Illness’, JAMA. American Medical Association, 284(20), p. 2606. doi: 10.1001/jama.284.20.2606. [PubMed: 11086367] [CrossRef]

  • Laursen, T. M. (2011) ‘Life expectancy among persons with schizophrenia or bipolar affective disorder’, Schizophrenia Research. Elsevier, 131(1–3), pp. 101–104. doi: 10.1016/J.SCHRES.2011.06.008. [PubMed: 21741216] [CrossRef]

  • de Leon, J. and Diaz, F. J. (2005) ‘A meta-analysis of worldwide studies demonstrates an association between schizophrenia and tobacco smoking behaviors’, Schizophrenia Research. Elsevier, 76(2–3), pp. 135–157. doi: 10.1016/J.SCHRES.2005.02.010. [PubMed: 15949648] [CrossRef]

  • Li, C. et al. (2017) ‘A systematic review and meta-analysis of randomized controlled trials of cognitive behavior therapy for patients with diabetes and depression’, Journal of Psychosomatic Research. [PubMed: 28314548]

  • Lieberman, J. A. et al. (2005) ‘Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia’, New England Journal of Medicine. Massachusetts Medical Society, 353(12), pp. 1209–1223. doi: 10.1056/NEJMoa051688. [PubMed: 16172203] [CrossRef]

  • Liu, N. H. et al. (2017) ‘Excess mortality in persons with severe mental disorders: a multilevel intervention framework and priorities for clinical practice, policy and research agendas.’, World psychiatry. World Psychiatric Association, 16(1), pp. 30–40. doi: 10.1002/wps.20384. [PMC free article: PMC5269481] [PubMed: 28127922] [CrossRef]

  • Lund, C. et al. (2013) ‘Mental illness and lost income among adult South Africans’, Social Psychiatry and Psychiatric Epidemiology, 48(5), pp. 845–851. doi: 10.1007/s00127-012-0587-5. [PMC free article: PMC3627034] [PubMed: 23007296] [CrossRef]

  • Mangurian, C. et al. (2017) ‘Low Rates of HIV Testing Among Adults With Severe Mental Illness Receiving Care in Community Mental Health Settings’, Psychiatric Services, 68(5), pp. 443–448. doi: 10.1176/appi.ps.201600248. [PubMed: 28093055] [CrossRef]

  • Maslej, M. M. et al. (2017) ‘The Mortality and Myocardial Effects of Antidepressants Are Moderated by Preexisting Cardiovascular Disease: A Meta-Analysis’, Psychotherapy and Psychosomatics. [PubMed: 28903117]

  • Mattick, R. P. et al. (2014) Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence’, The Cochrane database of systematic reviews, 2(2), p. CD002207. doi: 10.1002/14651858.CD002207.pub4.Copyright. [PMC free article: PMC10617756] [PubMed: 24500948] [CrossRef]

  • McLoughlin, B. C. et al. (2014) ‘Cannabis and schizophrenia’, Cochrane Database of Systematic Reviews. John Wiley & Sons, Ltd, (10). doi: 10.1002/14651858.CD004837.pub3. [PMC free article: PMC10107010] [PubMed: 25314586] [CrossRef]

  • Morrato, E. H. et al. (2009) ‘Metabolic Screening After the American Diabetes Association’s Consensus Statement on Antipsychotic Drugs and Diabetes’, Diabetes Care, 32(6), pp. 1037–1042. doi: 10.2337/dc08-1720. [PMC free article: PMC2681020] [PubMed: 19244091] [CrossRef]

  • Naslund, J. A. et al. (2017) ‘Lifestyle interventions for weight loss among overweight and obese adults with serious mental illness: A systematic review and meta-analysis’, General Hospital Psychiatry. [PMC free article: PMC5575752] [PubMed: 28807143]

  • NICE guidelines. Psychosis and schizophrenia in adults: prevention and management (Clinical guideline [CG178]; Published date: February 2014 Last updated: March 2014.

  • NICE guidelines Bipolar disorder: assessment and management (Clinical guideline [CG185]; Published date: September 2014 Last updated: February 2016.

  • NICE guidelines Depression in adults with a chronic physical health problem: recognition and management (Clinical guideline [CG91]; Published date: October 2009.

  • Nielsen, R. E. et al. (2013) ‘Increasing mortality gap for patients diagnosed with schizophrenia over the last three decades — A Danish nationwide study from 1980 to 2010’, Schizophrenia Research. Elsevier, 146(1–3), pp. 22–27. doi: 10.1016/J.SCHRES.2013.02.025. [PubMed: 23523021] [CrossRef]

  • Nieuwsma, J. A. et al. (2017) ‘Diagnostic accuracy of screening tests and treatment for post-acute coronary syndrome depression’, Annals of Internal Medicine. [PubMed: 29132152]

  • Nugent, K. L. et al. (2015) ‘Cumulative stress pathophysiology in schizophrenia as indexed by allostatic load.’, Psychoneuroendocrinology. NIH Public Access, 60, pp. 120–9. doi: 10.1016/j.psyneuen.2015.06.009. [PMC free article: PMC4526449] [PubMed: 26142568] [CrossRef]

  • Patel, M. X. et al. (2014) ‘Quality of prescribing for schizophrenia: Evidence from a national audit in England and Wales’, European Neuropsychopharmacology, 24(4), pp. 499–509. doi: 10.1016/j.euroneuro.2014.01.014. [PubMed: 24491953] [CrossRef]

  • Poon, A. W. C. et al. (2017) ‘A longitudinal population-based study of carers of people with psychosis’, Epidemiology and Psychiatric Sciences. Cambridge University Press, 26(3), pp. 265–275. doi: 10.1017/S2045796015001195. [PMC free article: PMC6998635] [PubMed: 26847994] [CrossRef]

  • Rosenberg, S. D. et al. (2010) ‘Assessing the STIRR Model of Best Practices for Blood-Borne Infections of Clients With Severe Mental Illness’, Psychiatric Services, 61(9), pp. 885–891. doi: 10.1176/ps.2010.61.9.885. [PMC free article: PMC3632357] [PubMed: 20810586] [CrossRef]

  • Sacchetti, E., Turrina, C. and Valsecchi, P. (2010) ‘Cerebrovascular accidents in elderly people treated with antipsychotic drugs: a systematic review’, Drug Saf., 33(4), pp. 273–288. doi: 2 [pii] 10.2165/11319120-000000000-00000. [PubMed: 20297860] [CrossRef]

  • Saha, S., Chant, D. and McGrath, J. (2007) ‘A systematic review of mortality in Schizophrenia: is the differential mortality gap worsening over time?’, Archives of General Psychiatry, 64(10), pp. 1123–31. doi: 10.1001/archpsyc.64.10.1123. [PubMed: 17909124] [CrossRef]

  • Saloojee, S., Burns, J. K. and Motala, A. A. (2014) ‘Very low rates of screening for metabolic syndrome among patients with severe mental illness in Durban, South Africa’, BMC Psychiatry, 14(1), p. 228. doi: 10.1186/s12888-014-0228-5. [PMC free article: PMC4149236] [PubMed: 25113131] [CrossRef]

  • Senn, T. E. and Carey, M. P. (2009) ‘HIV testing among individuals with a severe mental illness: review, suggestions for research, and clinical implications’, Psychological Medicine, 39(03), p. 355. doi: 10.1017/S0033291708003930. [PMC free article: PMC2640447] [PubMed: 18606051] [CrossRef]

  • de Silva, V. A. et al. (2016) ‘Metformin in prevention and treatment of antipsychotic induced weight gain: a systematic review and meta-analysis’, BMC Psychiatry. 2016/10/08. [PMC free article: PMC5048618] [PubMed: 27716110]

  • Ski, C. F. et al. (2016) ‘Psychosocial interventions for patients with coronary heart disease and depression: A systematic review and meta-analysis’, European Journal of Cardiovascular Nursing. [PubMed: 26475227]

  • Susser, E., Valencia, E. and Conover, S. (1993) ‘Prevalence of HIV infection among psychiatric patients in a New York City men’s shelter.’, American Journal of Public Health, pp. 568–570. [PMC free article: PMC1694479] [PubMed: 8460736]

  • Taylor, J. et al. (2017) ‘The Effectiveness of Pharmacological and Non-Pharmacological Interventions for Improving Glycaemic Control in Adults with Severe Mental Illness: A Systematic Review and Meta-Analysis’, PLoS One. [PMC free article: PMC5215855] [PubMed: 28056018]

  • Teasdale, S. B. et al. (2017) ‘Solving a weighty problem: systematic review and meta-analysis of nutrition interventions in severe mental illness’, Br J Psychiatry. [PubMed: 27810893]

  • Temmingh, H. S. et al. (2018) ‘Risperidone versus other antipsychotics for people with severe mental illness and co-occurring substance misuse’, Cochrane Database of Systematic Reviews. [PMC free article: PMC6491096] [PubMed: 29355909]

  • Trainor, K. and Leavey, G. (2017) ‘Barriers and Facilitators to Smoking Cessation Among People With Severe Mental Illness: A Critical Appraisal of Qualitative Studies’, Nicotine & Tobacco Research, 19(1), pp. 14–23. doi: 10.1093/ntr/ntw183. [PubMed: 27613905] [CrossRef]

  • Tsuang, M. T., Woolson, R. F. and Fleming, J. A. (1980) ‘Premature Deaths in Schizophrenia and Affective Disorders’, Archives of General Psychiatry. American Medical Association, 37(9), p. 979. doi: 10.1001/archpsyc.1980.01780220017001. [PubMed: 7416910] [CrossRef]

  • Tully, P. J. and Baumeister, H. (2015) ‘Collaborative care for comorbid depression and coronary heart disease: A systematic review and meta-analysis of randomised controlled trials’, BMJ Open. [PMC free article: PMC4691772] [PubMed: 26692557]

  • United Nations (2016) Annex IV: Final list of proposed Sustainable Development Goal indicators. Report of the Inter-Agency and Expert Group on Sustainable Development Goal Indicators.

  • Vahdat, S. et al. (2014) ‘Patient Involvement in Health Care Decision Making: A Review’, Iranian Red Crescent Medical Journal. doi: 10.5812/ircmj.12454. [PMC free article: PMC3964421] [PubMed: 24719703] [CrossRef]

  • Vancampfort, D. et al. (2016) ‘Diabetes mellitus in people with schizophrenia, bipolar disorder and major depressive disorder: A systematic review and large scale meta-analysis’, World Psychiatry, 15(2), pp. 166–174. doi: 10.1002/wps.20309. [PMC free article: PMC4911762] [PubMed: 27265707] [CrossRef]

  • Vancampfort, D. et al. (2017) ‘Sedentary behavior and physical activity levels in people with schizophrenia, bipolar disorder and major depressive disorder: a global systematic review and meta-analysis.’, World psychiatry. World Psychiatric Association, 16(3), pp. 308–315. doi: 10.1002/wps.20458. [PMC free article: PMC5608847] [PubMed: 28941119] [CrossRef]

  • Verschueren, S. et al. (2018) ‘The effect of exercise therapy on depressive and anxious symptoms in patients with ischemic heart disease: A systematic review’, Journal of Psychosomatic Research. [PubMed: 29332638]

  • Watson, K. et al. (2017) ‘Insulin resistance, an unmasked culprit in depressive disorders: Promises for interventions’, Neuropharmacology. Pergamon. doi: 10.1016/J.NEUROPHARM.2017.11.038. [PubMed: 29180223] [CrossRef]

  • Whiteford, H. A. et al. (2015) ‘The Global Burden of Mental, Neurological and Substance Use Disorders: An Analysis from the Global Burden of Disease Study 2010’, PLoS ONE, 10(2). doi: 10.1371/journal.pone.0116820. [PMC free article: PMC4320057] [PubMed: 25658103] [CrossRef]

  • WHO. (2008) WHO Report on the Global Tobacco Epidemic 2008: the MPOWER Package. World Health Organization.

  • Wilson, R. P. and Bhattacharyya, S. (2016) ‘Antipsychotic efficacy in psychosis with co-morbid cannabis misuse: A systematic review’, J Psychopharmacol. [PubMed: 26510450]

  • World Health Organization (2013) Mental Health Action Plan (2013–2020).

  • World Health Organization (2015) Meeting report on excess mortality in persons with severe mental disorders.

  • World Health Organization Regional Office for Europe (2016) Addressing comorbidity between mental disorders and major noncommunicable diseases.

  • Yang, C. et al. (2018) ‘Does antipsychotic drug use increase the risk of long term mortality? A systematic review and meta-analysis of observational studies.’, Oncotarget. Impact Journals, LLC, 9(19), pp. 15101–15110. doi: 10.18632/oncotarget.24120. [PMC free article: PMC5871101] [PubMed: 29599930] [CrossRef]